AZNCF - Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships
2024-07-28 01:24:46 ET
Summary
- Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates.
- The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties.
- ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology.
- Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs.
- Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks.
...
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships